Study #2018-0933
A Phase 1 Study Of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, For Patients With Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)
MD Anderson Study Status
Enrolling
Treatment Agent
Cemiplimab
Description
This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC). The aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as REGN2810). The first part of the study tested several different doses of cemiplimab given weekly for 12 weeks. The study is also looking at several other research questions, including: * What side effects may happen from taking the study drug * To see effect of cemiplimab on the tumor * How much study drug is in the blood at different times
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Study phase:
Phase I
Physician name:
Michael Migden
Department:
Dermatology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.